Amylyx Will Submit ALS Drug For Approval In The Coming Months

Continues ‘As Fast As Possible’ Approach With AMX0035

After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.

Physiotherapist assisting a patient with Amyotrophic Lateral Sclerosis — AMX0035 slowed disease progression in CENTAUR as assessed by an ALS functional rating scale • Source: Alamy

Amylyx Pharmaceuticals, Inc. said on 15 September that it will submit a new drug application (NDA) to the US Food and Drug Administration “in the coming months” seeking approval for AMX0035 to treat amyotrophic lateral sclerosis (ALS), well before completion of its soon-to-be-initiated Phase III clinical trial. The FDA filing plan is a shift from just two months ago when the Cambridge, MA-based private company, which intends to commercialize its drug globally on its own, raised $135m to fund the Phase III study and file AMX0035 with Canadian and EU regulators.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.